inHEART Models vs EchoGo Amyloidosis
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 60/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
inHEART Models is designed for optimizing cardiac ablation procedures through detailed 3D heart models derived from CT/MR images, aiding in surgical planning and execution. In contrast, EchoGo Amyloidosis is an AI-powered screening tool that analyzes echocardiogram video clips to assist in the early detection of cardiac amyloidosis. While both leverage AI in cardiology, their distinct focus areas are interventional procedure planning versus diagnostic screening for a specific disease.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
inHEART Models is an AI-driven software designed to optimize the planning and execution of image-guided cardiac ablation procedures, particularly for ventricular tachycardia (VT) ablations, by creating detailed 3D digital twin models of the heart. EchoGo Amyloidosis is an AI-powered screening tool that analyzes echocardiogram video clips to aid in the early detection of cardiac amyloidosis.
inHEART Models creates 3D digital twin models from CT or MR images. EchoGo Amyloidosis analyzes echocardiogram video clips, specifically a 2D echocardiogram of an apical four chamber (A4C), to identify patients at risk of cardiac amyloidosis.
inHEART Models provides highly detailed, interactive 3D cardiac models for pre-procedural planning and optimization of treatment strategies for ablations. EchoGo Amyloidosis provides a diagnostic output of 'suggestive' or 'not suggestive' of cardiac amyloidosis, based on AI-powered analysis of echocardiographic markers, with insights automatically sent to clinicians.
inHEART Models offers seamless integration with major electroanatomic mapping (EAM) systems such as Cartou00ae, Rhythmu2122ufe0f, Ensiteu2122ufe0f, and Afferau2122ufe0f. EchoGo Amyloidosis integrates seamlessly with existing clinical workflows and IT infrastructure, including PACS, DICOM, and HL7.
inHEART Models has shown the potential to reduce VT procedure times by 60% and VT recurrence rates by 38%. EchoGo Amyloidosis demonstrates high diagnostic accuracy with 85% sensitivity and 93% specificity for identifying suspected cardiac amyloidosis, with consistent performance across CA subtypes.